Add office photos
Engaged Employer
Cipla
4.1
based on 6.9k Reviews
Video summary
Top Rated Pharma Company - 2024
Company Overview
Associated Companies
Company Locations
Working at Cipla
Company Summary
Cipla is a leading Global Pharmaceutical Company that ensures access to quality & affordable medicines through various products across various therapeutic categories.
Overall Rating
4.1/5
based on 6.9k reviews
5% above
industry average
Highly rated for
Salary, Skill development, Company culture
Work Policy
Work from office
73% employees reported
Alternate Saturday off
38% employees reported
Flexible timing
57% employees reported
Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
598 employees reported
Health insurance
570 employees reported
Office cab/shuttle
272 employees reported
Professional degree assistance
194 employees reported
View all benefits
Rate your company
🤫 100% anonymous
How was your last interview experience?
Share interview
About Cipla
Founded in1935 (90 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitecipla.com
Primary Industry
Other Industries
View in video summary
At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades. Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
AmbitionBox Best Places to Work in India Awards
Best of the best, rated by employees
Cipla won India’s Largest Employee Choice Awards in Large Companies Category.
#2 Top Rated Pharma Company
Share
Cipla Ratings
based on 6.9k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.4k
4
1.9k
3
833
2
290
1
459
Category Ratings
4.0
Salary
4.0
Skill development
3.9
Company culture
3.9
Work-life balance
3.8
Work satisfaction
3.7
Job security
3.6
Promotions
Cipla is rated 4.1 out of 5 stars on AmbitionBox, based on 6.9k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Cipla
based on 6.5k reviews
4.1
Rated by 682 Women
Rated 3.9 for Work-life balance and 3.8 for Company culture
4.1
Rated by 5.8k Men
Rated 4.0 for Salary and 4.0 for Skill development
Work Policy at Cipla
based on 774 reviews in last 6 months
Work from office
73%
Hybrid
23%
Permanent work from home
4%
Cipla Reviews
Top mentions in Cipla Reviews
+ 5 more
Saint-Gobain
We thank our employees for rating us 
4/5 on AmbitionBox
4/5 on AmbitionBoxJoin a company where our employee's ratings speak volumes.
Compare Cipla with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.9k reviews  | 4.2/5 based on 6k reviews | 4.0/5 based on 5.8k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Salary Work-life balance | Skill development Company culture Work-life balance | Salary Skill development Job security | Skill development Work-life balance Salary |
Critically Rated for |  No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 73% employees reported | Work from office 85% employees reported | Work from office 82% employees reported | - |
Rating by Women Employees | 4.1 Good rated by 682 women | 4.0 Good rated by 361 women | 4.0 Good rated by 437 women | - no rating available |
Rating by Men Employees | 4.1 Good rated by 5.8k men | 4.2 Good rated by 5.4k men | 4.0 Good rated by 5k men | - no rating available |
Job security | 3.7 Good | 3.7 Good | 3.8 Good | 4.0 Good |
View more
Cipla Salaries
Cipla salaries have received with an average score of 4.0 out of 5 by 6.9k employees.
Deputy Manager
(1.1k salaries)
Unlock
₹5.3 L/yr - ₹18.3 L/yr
Therapy Manager
(502 salaries)
Unlock
₹2.4 L/yr - ₹7.1 L/yr
Area Business Manager
(500 salaries)
Unlock
₹4.4 L/yr - ₹12 L/yr
Territory Manager
(331 salaries)
Unlock
₹1.5 L/yr - ₹8 L/yr
Medical Representative
(316 salaries)
Unlock
₹1.9 L/yr - ₹7 L/yr
Regional Business Manager
(277 salaries)
Unlock
₹8 L/yr - ₹19.5 L/yr
Production Officer
(233 salaries)
Unlock
₹1 L/yr - ₹9.8 L/yr
Trainee
(192 salaries)
Unlock
₹1.2 L/yr - ₹4.5 L/yr
Maintenance Engineer
(192 salaries)
Unlock
₹1.5 L/yr - ₹6.4 L/yr
Area Sales Manager
(187 salaries)
Unlock
₹4.5 L/yr - ₹11.1 L/yr
Cipla Interview Questions
Interview questions by designation
Top Cipla interview questions and answers
Get interview-ready with top interview questions
Cipla Jobs
Current Openings
Cipla News
View all
Pfizer v. Softgel: The Errors of Comity
- The Madras High Court passed an order related to an ongoing patent dispute concerning Cipla’s and Zenara's ANDA applications seeking approval to market generic versions of Vyndamax in the US against Pfizer's US patent.
- Pfizer requested a Letter Rogatory to the Madras High Court for assistance in obtaining documents from an Indian company, Softgel Healthcare Private Limited, to be used in the proceedings.
- The Madras High Court upheld the principle of judicial assistance but failed to thoroughly check the information sought in the Letter Rogatory.
- A Letter Rogatory is a request for judicial assistance between courts of different countries, based on the principle of comity.
- Pfizer sought assistance from the Madras High Court to collect information and establish a confidentiality club, while Softgel opposed disclosure citing reasons like not being a party to the US suit and TRIPS regulations.
- The Madras High Court disregarded Softgel's arguments, dismissed concerns regarding the vagueness of information sought, and accepted the Letter Rogatory without fully understanding the information requested.
- The Court's decision raises questions about directing the collection of evidence from non-parties and the importance of assessing the relevance of documents, unlike the approach in the US courts.
- The US courts have additional qualifiers, including specificity, to determine requests for document discovery, unlike the Madras High Court's approach that prioritized upholding comity with the US court.
- The order by the Madras High Court could significantly impact the dispute's outcome, potentially affecting access to drugs like Vyndamax in the US which are priced at around $23,324 for a supply of 30 capsules.
Spicyip | 23 Feb, 2025
Stock Market Live: GIFT Nifty Above 22,800; Cipla, NTPC Green Energy, Vedanta Share Prices In Focus
- The GIFT Nifty was trading above 22,800.
- Cipla, NTPC Green Energy, and Vedanta share prices are in focus.
- Eris Lifesciences has availed credit facilities worth Rs 100 crore from Kotak Mahindra Bank Ltd.
- Mahindra & Mahindra Ltd. plans to fully subscribe to its rights entitlement in Mahindra Finance and Mahindra Life Development.
Bloomberg Quint | 21 Feb, 2025
Stock Market Today: All You Need To Know Going Into Trade On Feb. 21
- The NSE Nifty 50 and BSE Sensex closed lower on Thursday, with underperformance in financial heavyweights like HDFC Bank Ltd. and ICICI Bank Ltd.
- Foreign portfolio investors were net sellers while domestic institutional investors continued buying streak for the 12th session.
- The Indian rupee strengthened against the US dollar, closing at Rs 86.66 per dollar.
- Earnings post market hours showed mixed results with CIE Automotive and Sanofi Consumer reporting changes in revenue, Ebitda, and net profit.
- Stocks to watch include JM Financial, NTPC Green Energy, Vedanta, Religare Enterprises, Cipla, and more as they make significant announcements.
- Bulk deals and insider trading activities were highlighted for companies like Isgec Heavy Engineering, Sai Life Sciences, and others.
- Listing day for Quality Power Electrical Equipments is set for Friday after a successful IPO subscription rate.
- Trading tweaks included companies moving in and out of the Short-Term ASM Framework, F&O cues, and research reports from ICICI Securities, Anand Rathi, DRChoksey, and more.
- Overall, the stock market today reflected a mix of company performances, investor activities, and future outlooks.
- For more updates, viewers can watch live TV, get stock market updates, top business, IPO news on NDTV Profit.
Bloomberg Quint | 21 Feb, 2025
Glenmark’s US plant to gain amid geopolitical shifts, says CMD
- Glenmark's US plant expected to benefit from geopolitical shifts.
- Cipla and Piramal Pharma also highlight the advantages of having facilities in the US.
- Glenmark optimistic about US market with upcoming product launches.
- In India, Glenmark plans to launch more GLP-1 products for diabetes treatment.
HinduBusinessLine | 17 Feb, 2025
InTime Fire Appliances Pvt. Ltd. Leads the Charge in Comprehensive Fire Safety Solutions Across India
- InTime Fire Appliances Pvt. Ltd. is a pioneer in fire safety solutions in India.
- The company offers tailored fire safety solutions for diverse industries, focusing on quality, innovation, and customer-centricity.
- Their expertise includes clean agent systems, kitchen hood fire suppression systems, lithium battery fire extinguishers, and more.
- InTime Fire Appliances Pvt. Ltd. serves renowned clients such as Tata Steel, Cipla, HDFC, ONGC, and PVR.
Startupreporter | 13 Feb, 2025
Sensex, Nifty extend gains on Metal, Pharma rally; IT stocks drag
- Metal and pharmaceutical stocks led the rally, with Tata Steel emerging as the top gainer on the NSE, surging 3.79%.
- The healthcare sector saw strong performance from Sun Pharma and Cipla, advancing 2.77% and 2.68% respectively.
- Financial stocks, including Bajaj Finance and Bajaj Finserv, also contributed significantly to the gains.
- However, the technology sector faced selling pressure, with major IT companies trading in the red.
HinduBusinessLine | 13 Feb, 2025
Gland Pharma Share Price Target 2025 2026 to 2030
- Hyderabad-based pharmaceutical company Gland Pharma supplies injectables to over sixty countries.
- Gland Pharma shares have seen both short-term and long-term investors, and the stock's performance is under close observation.
- The Gland Pharma Share Price Target for 2025 is predicted to be between INR 1,813 to INR 2,827.
- From 2026 to 2030, Gland Pharma's share price target is projected at a minimum of INR 2,318 and a maximum of INR 6,680.08 in 2030.
- Gland Pharma's competitors include Sun Pharma, CIPLA, Divis Labs, and Dr. Reddys Labs.
- Gland Pharma's share price history isn't very long, having been listed on the National Stock Exchange in 2020.
- On August 13th, 2021, the GLAND NSE stock hit its highest point of INR 4,287.
- Consulting expert advice for the stock market predictions is advisable, as the values provided in the article are based on predictions and may not be accurate.
- Investors would need to consider verified information from other sources to make informed decisions about their investments.
- The article includes the projected maximum and minimum prices for Gland Pharma share for every month in 2025 and year-wise projection for 2026 to 2030.
VIE Stories | 10 Feb, 2025
Nifty 50 Top Gainers And Losers On Feb. 6: Cipla, ITC To Trent
- Shares of ITC Hotels Ltd., Cipla Ltd. and Adani Ports & Special Economic Zone Ltd. were the top gainers among the NSE Nifty 50 stocks on Tuesday.
- Among the losers were shares of Trent Ltd., Bharat Electronics Ltd., Bharti Airtel Ltd., Titan Co., and NTPC Ltd.
- The NSE Nifty 50 closed 0.39% down at 23,603.35, while the BSE Sensex was 0.27% lower at 78,058.16.
- The NSE Nifty 50 and BSE Sensex closed lower for the second consecutive session on Thursday, as market participants awaited the outcome of the Reserve Bank of India’s Monetary Policy Committee meeting.
Bloomberg Quint | 6 Feb, 2025
Markets extend losses, Sensex down 298 points; ITC Hotels, Cipla buck trend
- Markets extend losses, Sensex down 298 points.
- ITC Hotels and Cipla gain, while Titan Company leads the losses.
- Nifty Bank and Nifty Midcap Select index decline.
- Tata Steel records highest trading volume among top losers.
HinduBusinessLine | 6 Feb, 2025
Stocks that will see action today: February 4, 2025
- Sun Pharmaceuticals promotes Aalok Shanghvi as Chief Operating Officer.
- JTL Industries establishes new facility for manufacturing lattice towers.
- Solex Energy commissions new 800 MW production line for manufacturing TOPcon rectangular cell-based modules.
- Cipla Ltd to invest ZAR 900 million in equity share capital of its South African arm Cipla Medpro South Africa Proprietary Ltd.
HinduBusinessLine | 4 Feb, 2025
Powered by
Cipla Subsidiaries
Cipla Health
4.1
• 306 reviews
Report error
Compare Cipla with
Biocon Limited
3.9
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
3.9
Torrent Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Alkem Laboratories
3.9
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Abbott
4.1
Alembic Pharmaceuticals
4.0
Ipca Laboratories
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.1
Akums Drugs & Pharmaceuticals Limited
4.4
Cadila Pharmaceuticals
3.5
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
4.0
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to Cipla
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.7k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.9k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.4k reviews
Cipla FAQs
When was Cipla founded?
Cipla was founded in 1935. The company has been operating for 90 years primarily in the Pharma sector.
Where is the Cipla headquarters located?
Cipla is headquartered in Mumbai, Maharashtra. It operates in 2 cities such as Mumbai, Hyderabad / Secunderabad. To explore all the office locations, visit Cipla locations.
How many employees does Cipla have in India?
Cipla currently has more than 25,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Cipla based on the number of reviews submitted on AmbitionBox.
Does Cipla have good work-life balance?
Cipla has a Work-Life Balance Rating of 3.9 out of 5 based on 6,800+ employee reviews on AmbitionBox. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Cipla work-life balance reviews for more details
Is Cipla good for career growth?
Career growth at Cipla is rated fairly well, with a promotions and appraisal rating of 3.6. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Cipla promotions/appraisals reviews for more detailed insights.
What are the pros of working in Cipla?
Working at Cipla offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, skill development and company culture, based on 6,800+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
